Middle East Cystic Fibrosis Association MECFA

MECFA Blog

Annual Scientific Conference

Oman Respiratory Society 2024 Conference & 9th Asian Pediatric Pulmonology Society Annual Scientific Conference will be held in Grand...

The Heartbreaking Reality of Cystic Fibrosis Care in Iraq: A Mother's Plea for Help

Meet Sara from Iraq, a courageous mother fighting an uphill battle to ensure her daughter, Rozhin, receives the care she desperately...

MECFA supports CF patients in Tunisia

Tunisia is home to about 250 people with cystic fibrosis (CF), which was first discovered in 1994. Tunisia's population is approximately...

International disparities in diagnosis and treatment access for cystic fibrosis

The elastacaftor/tezacaftor/ivacaftor (ETI) triple therapy has completely altered the course of treatment for cystic fibrosis (CF)....

Philip Hopewell Prize for Global Respiratory Health Research

We are delighted to announce the 2024 winner of The Philip Hopewell Prize for Global Respiratory Health Research. Congratulations to Dr....

South Africans take on big pharma for access to ‘miracle’ cystic fibrosis drug

Cheri Nel cannot afford Vertex’s Trikafta medicine, so she is suing to end ‘patent abuse’ and allow a generic version Cheri Nel has a...

MECFA launches campaign to help people with CF in Gaza and the West Bank, Palestine

MECFA, in its latest initiative, has launched the BreathForGaza campaign to support children and young adults in Gaza and the West Bank...

Ministry of Health unveils national electronic registry for cystic fibrosis patients

In a joint effort with the Quality Improvement Project for Health Services, the Jordanian Ministry of Health has released a nationwide...

MECFA Jordan Project report

Conquering chronic lung infection in cystic fibrosis patients

by American Society for Microbiology Cystic fibrosis (CF) is one of the most common genetic disorders in the world. The disease infects...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p